The Rosen Law Firm, a global investor rights law firm, announced a deadline for investors who purchased Biohaven Ltd. (NYSE: BHVN) securities. Investors who bought shares between March 24, 2023, and May 14, 2025, have until September 12, 2025, to apply to become the lead plaintiff in a class-action lawsuit.
The lawsuit alleges that Biohaven made misleading statements about the regulatory prospects of its drug, troriluzole, for the treatment of spinocerebellar ataxia (SCA), and the efficacy of BHV-7000 for bipolar disorder. The firm contends that these misrepresentations negatively impacted Biohaven‘s financial condition.
Rosen Law Firm encourages investors to choose legal counsel with a proven track record in securities class action lawsuits. They highlighted their own experience, including securing the largest-ever securities class action settlement against a Chinese company and consistently ranking among the top firms in the field. The firm emphasizes their extensive resources and experience in managing such complex cases.
The firm explains that the lead plaintiff will represent other class members in guiding the litigation. However, they clarified that participation in the lawsuit does not require becoming a lead plaintiff. Investors can choose to remain absent class members. The firm also noted that a class has not yet been certified.
Individuals who purchased Biohaven securities during the specified period are advised to contact Phillip Kim, Esq. at Rosen Law Firm for more information. The firm provided contact information, including a phone number and email address, for interested parties. The firm emphasized that their services are contingency-based, meaning investors pay no fees unless compensation is awarded.
Rosen Law Firm‘s announcement serves as a reminder to affected investors of their rights and the steps they can take to pursue potential compensation. The firm’s extensive experience in securities litigation provides context for their announcement, emphasizing the importance of choosing experienced legal representation. The deadline for lead plaintiff application underscores the time-sensitive nature of the legal proceedings.
Related
